The women were randomized 1:1, between 10–18 weeks of gestation, to a daily intake of 4,000 IU vitamin D3 plus a multivitamin containing 400 IU vitamin D3 or a matching placebo tablet plus a multivitamin containing 400 IU vitamin D3, i.e. 4,400 vs. 400 IU vitamin D3 supplement per day. The intervention was continued until delivery. Adherence was measured by MEMS® (Medication Events Monitoring Systems) caps, an electronic cap that recorded each time the tablet container was opened[7 (link)].
Blood was drawn from the mothers at entry to the trial and at the 3rd trimester visit (32 to 38 weeks of gestation) for measurement of circulating levels of 25(OH)D, determined by using the DiaSorin Liaison® chemiluminescence immunoassay[13 (link)].
Blood was drawn from the mothers at entry to the trial and at the 3rd trimester visit (32 to 38 weeks of gestation) for measurement of circulating levels of 25(OH)D, determined by using the DiaSorin Liaison® chemiluminescence immunoassay[13 (link)].
Free full text: Click here
